Loading...
Market
Will WHO report a 30% reduction in mpox cases in Africa by the end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
WHO official reports and statistics
Story
WHO Prequalifies Bavarian Nordic's MVA-BN as First Mpox Vaccine for Emergency Use
Sep 13, 2024, 10:24 AM
The World Health Organization (WHO) has prequalified Bavarian Nordic's MVA-BN vaccine as the first vaccine against mpox. This approval marks a significant step towards expanding access and reducing transmission in high-risk communities, particularly in Africa where the disease has been prevalent. The MVA-BN vaccine, which is also indicated for smallpox, is now eligible for procurement by UN agencies, facilitating broader distribution to those in need. WHO Director-General Dr. Tedros Adhanom Ghebreyesus emphasized the importance of this development in the fight against mpox. The vaccine has been approved for emergency use in adults.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Vaccination campaigns • 25%
Travel restrictions • 25%
Public awareness programs • 25%
Quarantine and isolation • 25%
Less than 750 • 25%
750 to 1,000 • 25%
1,001 to 1,250 • 25%
More than 1,250 • 25%
Less than 2,000 • 25%
2,000 to 3,000 • 25%
3,001 to 4,000 • 25%
More than 4,000 • 25%